The PHOENIX group continued to secure its position as Europe’s leading pharmaceutical trader in the fiscal year 2013/14, despite the challenging European market environment. Revenue rose by 2.7 per cent to EUR 21,792.4 million. This was due to the higher revenues in Finland, Italy, the Netherlands,…
read more